PDR001

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Solid TumorPatients With Advanced Solid TumorsParkinson's Disease

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

1

Yervoy

Bristol-Myers Squibb

Preclinical

32

Nubeqa

Bayer

Preclinical

23

Fludara

Sanofi

Preclinical

14

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

25

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

26

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

17

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

18

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

19

Tulmimetostat

Novartis

Preclinical

110

Carboplatin AUC-5

Merck & Co.

Preclinical

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Advanced Malignancies8 trials

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Terminated·Novartis·Phase 1·NCT03301896·45 enrolled

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Completed·Novartis·Phase 1/2·NCT02807844·141 enrolled

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Completed·Novartis·Phase 1/2·NCT02460224·490 enrolled

Show 5 more trials

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Terminated·Novartis·Phase 1/2·NCT02608268·252 enrolled

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Completed·Novartis·Phase 1·NCT02678260·18 enrolled

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Completed·Novartis·Phase 1/2·NCT02404441·319 enrolled

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Completed·Novartis·Phase 1·NCT02947165·120 enrolled

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Terminated·Novartis·Phase 1·NCT02936102·154 enrolled

Lymphoma3 trials

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Terminated·Novartis·Phase 1·NCT03172936·106 enrolled

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Terminated·Novartis·Phase 2·NCT03207867·315 enrolled

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Completed·Novartis·Phase 1·NCT02740270·92 enrolled

Colorectal Cancer2 trials

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Terminated·Novartis·Phase 1·NCT03176264·1 enrolled

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Unknown status·MMassachusetts General Hospital·Phase 2·NCT03668431·25 enrolled

Advanced Solid Tumors2 trials

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated·Novartis·Phase 1·NCT04237649·77 enrolled

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Terminated·Novartis·Phase 1/2·NCT02829723·192 enrolled

Malignancies2 trials

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Terminated·Novartis·Phase 1·NCT04895748·40 enrolled

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Completed·Novartis·Phase 1·NCT01351103·185 enrolled

19 more indications

Patients With Advanced Solid Tumors2 trials

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Terminated·Novartis·Phase 1·NCT02607813·142 enrolled

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Active, not recruiting·Novartis·Phase 1·NCT03891953·98 enrolled

Metastatic Melanoma1 trial

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Completed·Novartis·Phase 2·NCT03484923·196 enrolled

Solid Tumors1 trial

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Completed·Novartis·Phase 1/2·NCT02325739·172 enrolled

Melanoma1 trial

PDR001 + Panobinostat for Melanoma and NSCLC

Withdrawn·MMuhammad Furqan·Phase 1·NCT03982134

Parkinson's Disease1 trial

Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease

Recruiting·RRuijin Hospital·Phase 1·NCT07157345·12 enrolled

High Risk1 trial

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Completed·Novartis·Phase 1·NCT03066648·241 enrolled

Non-Small Cell Lung Cancer1 trial

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Unknown status·—·Phase 2·NCT03693326·70 enrolled

Maximum Tolerated Dose1 trial

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Completed·Novartis·Phase 1·NCT02988440·20 enrolled

Squamous Cell Carcinoma1 trial

Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Unknown status·YYonsei University·Phase 2·NCT03785496·44 enrolled

Neuroendocrine Carcinoma1 trial

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Completed·Novartis·Phase 2·NCT02955069·116 enrolled

Multiple Myeloma1 trial

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Completed·Novartis·Phase 1·NCT03111992·26 enrolled

Metastatic NSCLC1 trial

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Terminated·Novartis·Phase 1·NCT03064854·111 enrolled

Ovarian Cancer1 trial

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Terminated·—·Phase 1·NCT03294694·33 enrolled

Hematologic Malignancies1 trial

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Completed·Novartis·Phase 2·NCT03365791·76 enrolled

Metastatic Cancer1 trial

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Terminated·Novartis·Phase 1·NCT02452268·83 enrolled

Triple-Negative Breast Cancer1 trial

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Completed·Novartis·Phase 2·NCT03499899·88 enrolled

Thyroid Cancer1 trial

Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04544111·19 enrolled

Solid Tumor1 trial

An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments

Active, not recruiting·Novartis·Phase 1·NCT04058756·120 enrolled

Unspecified2 trials

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Completed·Novartis·Phase 1·NCT02900664·283 enrolled

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Completed·Novartis·Phase 1·NCT02890069·298 enrolled

Details

Drug Info

Related News